Cargando…
Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069848/ https://www.ncbi.nlm.nih.gov/pubmed/32185037 http://dx.doi.org/10.1002/ccr3.2688 |
_version_ | 1783505850479935488 |
---|---|
author | Nagashima, Kana Kikuchi, Shohei Iyama, Satoshi Fujita, Chisa Goto, Akari Horiguchi, Hiroto Kobune, Masayoshi |
author_facet | Nagashima, Kana Kikuchi, Shohei Iyama, Satoshi Fujita, Chisa Goto, Akari Horiguchi, Hiroto Kobune, Masayoshi |
author_sort | Nagashima, Kana |
collection | PubMed |
description | Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT. |
format | Online Article Text |
id | pubmed-7069848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70698482020-03-17 Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission Nagashima, Kana Kikuchi, Shohei Iyama, Satoshi Fujita, Chisa Goto, Akari Horiguchi, Hiroto Kobune, Masayoshi Clin Case Rep Case Reports Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT. John Wiley and Sons Inc. 2020-01-31 /pmc/articles/PMC7069848/ /pubmed/32185037 http://dx.doi.org/10.1002/ccr3.2688 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Nagashima, Kana Kikuchi, Shohei Iyama, Satoshi Fujita, Chisa Goto, Akari Horiguchi, Hiroto Kobune, Masayoshi Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
title | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
title_full | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
title_fullStr | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
title_full_unstemmed | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
title_short | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
title_sort | successful brentuximab vedotin monotherapy against late relapse of classical hodgkin lymphoma 6 years after first remission |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069848/ https://www.ncbi.nlm.nih.gov/pubmed/32185037 http://dx.doi.org/10.1002/ccr3.2688 |
work_keys_str_mv | AT nagashimakana successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT kikuchishohei successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT iyamasatoshi successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT fujitachisa successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT gotoakari successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT horiguchihiroto successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT kobunemasayoshi successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission |